566169-97-9

Usage

Uses

Used in Medical Imaging:
Benzenamine, 4-(6-bromo-2-benzothiazolyl)-, is used as a β-amyloid PET (positron emission tomography) tracer for the diagnosis of neurological diseases. Its application is particularly relevant in identifying and monitoring the progression of conditions such as Alzheimer's and Down's syndrome. Benzenamine, 4-(6-bromo-2-benzothiazolyl)-'s ability to act as a tracer allows for the visualization of β-amyloid plaques, which are a hallmark of these neurodegenerative diseases, thus aiding in early detection and treatment planning.

Upstream product

• 1226795-30-7 2-(4'-nitrophenyl)-6-tributylstannylbenzothiazole 
• 43016-99-5 Tin (II) chloride 
• 23451-95-8 2-amino-5-bromobenzenethiol 
• 555-16-8 4-nitrobenzaldehdye 
• 566169-95-7 N-(4'-bromophenyl)-4-nitrothiobenzamide 
• 106-40-1 4-bromo-aniline 
• 122-04-3 4-nitro-benzoyl chloride 
• 59280-03-4 N-(4'-bromophenyl)-4-nitrobenzamide 
• 566169-96-8 6-bromo-2-(4-nitrophenyl)benzo[d]thiazole 
• 182499-80-5 2,2′-disulfanediylbis(4-bromoaniline) 
• 15864-32-1 2-amino-6-bromobenzothiazole 
• 150-13-0 4-amino-benzoic acid 

Downstream Products

• 566169-98-0 2-(4'-methylaminophenyl)-6-bromobenzothiazole 
• 1226795-31-8 2-(4'-N-tert-butyloxycarbonyl-methylaminophenyl)-6-bromobenzothiazole 
• 1374349-51-5 N-[4-(6-bromobenzo[d]thiazol-2-yl)phenyl]-N-methylformamide 
• 1374349-35-5 4-(6-bromobenzo[d]thiazol-2-yl)-N-(⁽¹¹⁾C-methyl)aniline 
• 1374349-44-6 N-[4-(6-bromobenzo[d]thiazol-2-yl)phenyl]-N-(⁽¹¹⁾C-methyl)formamide 
• 1374349-53-7 N-[4-(6-bromobenzo[d]thiazol-2-yl)phenyl]formamide 

Relevant academic research and scientific papers

Development of a radioiodinated thioflavin-T-Congo-red hybrid probe for diagnosis of systemic amyloidosis

Introduction: Systemic amyloidosis is a group of diseases characterized by the deposition of amyloid protein in multiple organs throughout the body and causing their dysfunction. As amyloid deposition is observed at an early phase and is highly specific t

Novel series of benzo[d]thiazolyl substituted-2-quinolone hybrids: Design, synthesis, biological evaluation and in-silico insights

A novel series of 3-(2-(4-(substituted-benzo[d]thiazol-2-yl)phenylamino)acetyl)-4?hydroxy-1-methyl/phenyl quinolin-2(1H)-one (7a-f and 8a-f) were synthesized. Reaction of appropriately substituted-2-(4-amino phenyl)benzo[d]thiazole (4a-f) with 3-(2-bromoacetyl)-4?hydroxy-1-methyl/phenyl quinolin-2(1H)-one (5/6) in the presence of glacial acetic acid resulted in desired compounds. Structures of the synthesized compounds were characterized based on their spectral (IR, 1H NMR, 13C NMR and MS) and elemental analysis. The cytotoxicity screening studies revealed that MCF-7 and WRL68 cancer cells were sensitive to all the tested compounds. Out of twelve novel hybrids, compound 8f displayed the most significant anticancer activity. Docking studies were performed in order to understand the binding mode of the title compounds at the active site of the target enzyme (EGFR tyrosine kinase, 1M17). Compounds 8f and 7f displayed prominent and conserved binding interactions against 1M17. In addition, compounds 7e, 7f, 8e, and 8f exhibited interesting in vitro antibacterial activity, especially against Gram-negative bacteria E. coli. In summary, the novel benzo[d]thiazolyl substituted-2-quinolone hybrid (8f) could be considered as promising hit and could be further exploited for developing potential anticancer/antimicrobial agents.

For the preparation and β Amyloid protein specific binding of the compound of compound, preparation method and application thereof (by machine translation)

One aspect of the invention discloses a compound, the compound has the structural formula X as shown in the structure, wherein the substituted group R1 Can be - NO2 It also can be thought that the - NHCH3 ; On the other ha

Compound for preparing compound specifically bound with beta amyloid protein, preparation method and application thereof

The invention discloses a compound on one hand, wherein the compound has a structure as shown in structural formula A as shown in the specification, and a substituent group R1 can be -NO2, and also can be -NH2; and the invention discloses application of t

COMPOUND FOR SPECIFICALLY BINDING TO AMYLOID ?-PROTEIN

Provided is a compound for specifically binding to amyloid β-protein. The compound has thereon a nuclide with a large thermal neutron capture cross section and the compound is capable of specifically binding to the amyloid β-protein. The property of the compound allows it to be used in conjunction with a neutron capture therapy device to eliminate amyloid β-protein. Similarly, when the compound is labelled with radioactive element 11C, the compound can also be used in conjunction with PET/CT for determining the part of the brain where amyloid β-protein is deposited, for diagnosing Alzheimer's disease. Also disclosed is a preparation process for the compound. The beneficial effect of the present disclosure is to make the therapy and diagnosis of Alzheimer's disease more targeted by providing the compound for specifically binding to amyloid β-protein.

Neutron capture therapy system for removing amyloid beta-protein employing neutron beam source to destroy structure of amyloid beta-protein for removal without damaging normal tissues

The present invention provides a neutron capture therapy system for removing amyloid beta-protein, which comprises a neutron capture therapy device and a compound containing nuclides with large thermal neutron capture crossed section capable of heterogene

Synthesis of 2-arylbenzothiazoles via direct condensation between in situ generated 2-aminothiophenol from disulfide cleavage and carboxylic acids

In this work we describe a simple and efficient general methodology for 2-arylbenzothiazole preparation employing disulfides and carboxylic acids. The reaction is promoted by tributylphosphine that acts both in disulfide bond cleavage and as activating agent for coupling with carboxylic acids. The reaction scope was studied using bis(2-aminophenyl)disulfide and different carboxylic acids with donor/withdrawing substituents, which resulted in the desired 2-arylbenzothiazole with moderate to good yields. The method was tested with success in preparation of the amyloid probe 2-(4-aminophenyl)-6-methoxybenzothiazole that employed a substituted bis(2-aminophenyl)disulfide.

Aromatic radiofluorination and biological evaluation of 2-aryl-6-[ 18F]fluorobenzothiazoles as a potential positron emission tomography imaging probe for β-amyloid plaques

To develop agents for radionuclide imaging Aβ plaques in vivo, we prepared three fluorine-substituted analogs of arylbenzothiazole class; compound 2 has a high affinity for Aβ (Ki = 5.5 nM) and the specific binding to Aβ in fluorescent staining. In preparation for the synthesis of these arylbenzothiazole analogs in radiolabeled form as an Aβ plaques-specific positron emission tomography (PET) imaging probe, we investigated synthetic route suitable for its labeling with the short-lived PET radionuclide fluorine-18 (t1/2 = 110 min) and diaryliodonium tosylate precursors (12, 13a-e and 14). 2-Aryl-6-[18F]fluorobenzothiazoles ([18F]1-3) were synthesized in efficiently short reaction times (40-60 min) with high radiochemical yields (19-40%), purities (>95%) and specific activities (85-118 GBq/μmol). Tissue distribution studies showed that high radioactivity of [18F]2 accumulated in the brain with rapid clearance in healthy mice. Radioactive metabolites were analyzed in brain samples of mice and corresponded to 81% of parent remained by 30 min after a tail-vein injection. These results suggest that [18F]2 is a promising probe for evaluation of Aβ plaques imaging in brain using PET.

FLUORINATED BENZOTHIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND IMAGING AGENT FOR DIAGNOSING ALTZHEIMER'S DISEASE USING THE SAME

The present invention relates to fluorinated benzothiazole derivatives, a preparation method thereof, and an imaging agent for diagnosing Alzheimer's disease using the same, and more particularly to fluorinated benzothiazole derivatives represented by Che

FLUORINATED BENZOTHIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND IMAGING AGENT FOR DIAGNOSING ALTZHEIMER'S DISEASE USING THE SAME

The present invention relates to fluorinated benzothiazole derivatives, a preparation method thereof, and an imaging agent for diagnosing Alzheimer' s disease using the same, and more particularly to fluorinated benzothiazole derivatives represented by Chemical Formula 1, derivatives of Chemical Formula 2 as a starting material for preparation thereof, a preparation method thereof, and an imaging agent for diagnosing Alzheimer's disease using fluorinated benzothiazole derivatives with a strong binding force to beta-amyloid plaque, which is a kind of biomarker for Alzheimer's disease. According to the present invention, fluorine-labeled benzothiazole derivatives, which have been difficult to synthesize by conventional methods, may be obtained by simple processes and the thus-obtained benzothiazole derivatives may be useful in diagnosing the presence and severity of Alzheimer's disease.